Postmarketing non-interventional safety study on medicinal product Buprenorphine Actavis 35; 52,5; 70 microgram/h transdermal patch in Czech Republic, No.1303010000

Study identification

• EU PAS number:
  EUPAS12041
• Study ID:
  12042
• Official title and acronym:
  Postmarketing non-interventional safety study on medicinal product Buprenorphine Actavis 35; 52,5; 70 microgram/h transdermal patch in Czech Republic, No.1303010000
• DARWIN EU® study:
  No
• Study countries:
  Czechia
• Study description:
  PASS searching and collecting reports on adverse drug reaction, possibility of follow-up of the development of the clinical status of a patient and analyze reports.
• Study status:
  Planned

Research institutions and networks

Institutions

Actavis

Study timelines

Date when funding contract was signed

Planned: 13/02/2013

Study start date

Planned: 04/03/2013

Data analysis start date

Planned: 28/02/2016

Date of final study report

Planned: 31/12/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Actavis

Regulatory

• Was the study required by a regulatory body?:
  No